Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety, and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Open Plain Language Summary Result: